AI Startup-Pharma Partnership Tracker
Krzysztof Potempa
Dreamster dedicated to the prevention and treatment of mental health disorders that affect at least 1 in 6 people worldwide!
Latest update: 15 November 2024
Almost 100 partnerships have been identified between AI vendors and Big Pharma companies since 2015, with increasing numbers witnessed in recent years. GlobalData analysis shows that there were four partnerships for AI-based drug discovery forged by Big Pharma in 2015. In 2020, 27 partnerships in this field were identified, an increase of 575% in just six years. Full story: Big Pharma forging more partnerships with AI vendors for drug discovery ( clinicaltrialsarena.com ) .
Tracked AI-Pharma Partnerships:
November 2024: Novartis pays Schr?dinger $150M to form drug discovery pact; Schr?dinger is in line to receive up to $892 million in R&D and regulatory milestones plus $1.38 billion in commercial payouts and royalties on net sales for each product commercialized by Novartis. Schr?dinger announces collaboration with Novartis | Pharmaceutical | The Pharmaletter | The Pharmaletter Schr?dinger’s (Nasdaq: SDGR) shares leapt nearly 14% to $22.25 on the back of news that it has entered into a research collaboration and license agreement with Novartis. Schr?dinger, Inc. - Schr?dinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
AI Collaboration Between Sanofi and Healx Will Target Novel Rare Diseases Indications. Under the terms of the agreement, Sanofi will provide data related to the unnamed drug compound, which is being considered for out-licensing, and Healx will use Healnet, its AI-driven drug discovery platform, to identify diseases that the compound could potentially treat. The company will also provide Sanofi’s scientists with an AI-based therapeutic rationale to support the compound’s future development.?Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform - Healx
September 2024: Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery;
Lilly-backed Superluminal speeds toward the clinic with $120M ( fiercebiotech.com ) ; Lilly, Haya ink $1B biobuck obesity pact to search dark genome ( fiercebiotech.com ); Eli Lilly jumps deeper into AI with $409M Genetic Leap deal | Fierce Biotech
Novo Nordisk may pay up to $600 million in upfront, development, and commercial milestone payments to Metaphore Metaphore ( metaphorebio.com )
Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design ( prnewswire.com )
April 2024: Sonrai Analytics and Candel to advance cancer treatment using AI ( pharmaceutical-technology.com )
January 2024: Novo Nordisk will open AI hub in London | pharmaphorum and Isomorphic lands deals with Lilly, Novartis worth nearly $3B ( fiercebiotech.com )
December 2023: Fauna Bio Announces Strategic Collaboration with Lilly to Discover Novel Obesity Targets Using Convergence? AI Platform ( prnewswire.com )
Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim ( prnewswire.com )
Novo Nordisk, Valo to develop cardiometabolic disease therapies ( pharmaceutical-technology.com ) and Novo Nordisk pays $60M for AI-powered cardio collab with Valo ( fiercebiotech.com ) and Valo | Valo Health and Novo Nordisk to collaborate to discover and…
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery | Merck ( merckgroup.com ) and Merck KGaA taps BenevolentAI, Exscientia for AI drug discovery ( fiercebiotech.com ) and BenevolentAI Signs Strategic Collaboration with Merck | BenevolentAI (AMS: BAI)
领英推荐
8 November 2022: Sanofi will pay Insilico Medicine a total of up to $21.5 million to benefit from https://Pharma.AI and access a team of drug discovery scientists to identify, synthesize & advance high-quality lead therapeutic compounds up to development candidate stage in a deal worth up to $1.2 billion. Full story: Sanofi signs latest billion-dollar AI drug discovery deal | VentureBeat
6 October 2022: Lilly inks $425M biobuck drug discovery pact with Schr?dinger (fiercebiotech.com) Under the terms of the deal, Schr?dinger will discover and optimize small-molecule compounds against the target before handing off to Lilly for the completion of preclinical development and all subsequent work
21 September 2022: Pfizer ?will invest $20 million in equity, hold options for licencing the platform and disease models of CytoReason, and provide additional funding for supporting supplementary projects in a deal worth up to $110 million. Full story: Pfizer and CytoReason extend partnership for AI-driven drug discovery (pharmaceutical-technology.com)
12 September 2022: Microsoft is providing AI technology, foundational science models, and expertise and is working alongside Novo Nordisk’s data scientists and domain experts to accelerate Novo Nordisk’s research and development. One use case is focused on automated summarization and analysis of information from sources such as literature, patents, scientific reports, and discussion forums in order to gain novel scientific insights. A second use case aims to develop models that predict a person’s risk of developing atherosclerosis, a cardiovascular disease caused by build-up of fats, cholesterol, and other substances in and on the artery walls. Full story: Novo Nordisk and Microsoft collaborate to fast-track drug discovery through AI | HealthCare Africa Magazine
7 September 2022 Brainomix and Bridge Biotherapeutics enter artificial intelligence partnership - PharmaTimes
17 August 2022: Sanofi pay $20 million upfront, to leverage AtomNet platform to research small molecules aimed at up to five drug targets. If the collaboration proves fruitful, Atomwise could be in line for up to $1 billion in research, development and sales milestones as well as tiered royalties. Full story: Sanofi signs $1.2B pact with Atomwise in latest AI deal (fiercebiotech.com)
1 June 2022 Merck KGaA, South Korea's Standigm team up for AI-based drug discovery research | Seeking Alpha Under the Memorandum of Understanding (MOU),?Standigm will accelerate its drug discovery research by adopting Merck's AI software?Synthia ?which can help Standigm's novel compound synthesis. "By pooling know-how in AI synthesis of Merck and Standigm's AI technology together, we expect better results in drug discovery faster, compared to the traditional AI drug discovery method," said?Standigm Co-Founder and CEO?Sojeong Yun.
14 January 2022: BenevolentAI and AstraZeneca expand drug discovery partnership (pharmaceutical-technology.com) . The three-year collaboration extension comprises an upfront payment, funding for research, payments on meeting development milestones and tiered royalty payments on revenues in the future. The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF-AstraZeneca forms drug discovery alliance with BenevolentAI (pharmaceutical-technology.com) .
7 January 2022: After working with AI drug discovery shop Exscientia for five years, Sanofi has?significantly expanded its relationship , putting up $100 million and $5.2 billion on the backend for the chance to work on up to 15 small molecules across oncology and immunology. Full story: Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia | Fierce Biotech
7 December 2021 Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology (prnewswire.com) . Under the terms of the agreement, Recursion will receive an upfront payment of?$150 million?and is eligible for additional performance-based research milestones. Under the collaboration, Roche and Genentech (combined) may initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than?$300M?in development, commercialization and net sales milestones for Recursion, as well as tiered royalties on net sales.
18 November 2021: Sanofi inks two-part deal with Owkin that includes a?$180 million equity investment ?in the company alongside a $90 million discovery and development partnership that spans the next three years, plus the chance for additional milestone-based payments based on the pair’s success. Full story: Sanofi inks $270M cancer AI deal with R&D platform developer Owkin | Fierce Biotech
28 July 2021: AbbVie and Calico extend partnership on drugs for age-related diseases (pharmaceutical-technology.com) . The companies will co-invest nearly $1 billion for the alliance, which will extend until 2025. Since 2014, the parentship has generated about 20 early-stage programmes targeting disease states in areas of immuno-oncology and neurodegeneration. Three neurodegeneration and cancer targets were progressed to clinical trials by the companies, which also have a robust preclinical pipeline. AbbVie hits go on $1B re-upped Calico deal as the Google life science spinout continues I-O, neuro push | Fierce Biotech
10 December 2019 Boehringer Ingelheim has partnered with UK-based drug technology firm Healx to identify approaches to treat rare neurological disorders. Full story: Boehringer partners with Healx for AI-based drug discovery (pharmaceutical-technology.com)
16 April 2019 Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis | Business Wire Under the terms of the agreement, insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. insitro will be eligible to receive up to $200 million for the achievement of preclinical, development, regulatory and commercial milestones for each of the five Gilead targets; and up to low double-digit tiered royalties on net sales. For programs where insitro opts in, it will have the right to co-develop and co-detail in the U.S., receive a profit share in China and receive milestone payments and royalties on other ex-U.S. sales.
Source: Artificial intelligence in drug development: present status and future prospects - ScienceDirect and AI-powered drug discovery captures pharma interest | Nature Biotechnology
Further readings
November 2022: Artificial Intelligence and Machine Learning in Drug Discovery (Part I) - Drug Hunter
31 January 2020 Japanese giant Sumitomo Dainippon Pharma and Oxford-headquartered AI-driven drug discovery company Exscientia yesterday announced that they have created a new compound which is in the process of entering human clinical trials in Japan. Full story: Sumitomo Dainippon Pharma and Exscientia achieve breakthrough in AI drug discovery | Healthcare IT News and Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study | IR News | Investor Relations | Sumitomo Pharma (sumitomo-pharma.com)
Resident Physician, Scientist
2 年These are very well done. Thank you!